Rallybio (RLYB) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed Spero Therapeutics (SPRO) over the past year, gaining 208.4% versus a loss of 67.9%. Over five years, RLYB leads with a -85.3% price change compared with -95.1% for SPRO. Rallybio is the larger company by market cap ($43.3 million vs $43.2 million), about 1.0 times the size, while Spero Therapeutics is growing revenue faster (+39.2% vs +34.9%).
Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -1046.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLYB | SPRO |
|---|---|---|
| Share price | $15.47 | $0.742 |
| Market cap | $43.32M | $43.23M |
| 1-day change | -0.32% | -10.20% |
| YTD return | +181.89% | -68.15% |
| 1-year return | +208.41% | -67.88% |
| 5-year return | -85.29% | -95.09% |
| P/E ratio (TTM) | 3.36 | — |
| EPS (TTM) | $4.61 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $858.00K | $66.80M |
| Revenue growth (YoY) | +34.91% | +39.24% |
| Net income (latest FY) | $-8.98M | $8.57M |
| Operating margin | -3853.61% | 9.45% |
| Net margin | -1046.39% | 12.83% |
| 52-week high | $35.15 | $3.08 |
| 52-week low | $7.34 | $0.73 |
| Distance from 52-week high | -55.99% | -75.91% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +573.85% |
| Average volume | 10.14K | 530.46K |
| Shares outstanding | 2.80M | 58.26M |
| Employees | 7 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed SPRO by 276.3 percentage points over the past year.
- Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -1046.4 cents for Rallybio.
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
RLYB vs SPRO FAQ
Which is bigger, Rallybio or Spero Therapeutics?
Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $43.23M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, RLYB or SPRO?
RLYB returned +208.41% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Rallybio and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.